StockIQpro
NASDAQ:SILO

Silo Pharma, Inc.

Track all markets on TradingView
Track all markets on TradingView

Silo Pharma, Inc.'s revenue was essentially unchanged in fiscal 2025 at $72,102 while operating margin rose to −5937.0%. The diluted share count rose 127.8%.Summary generated from Silo Pharma, Inc.'s SEC filings. Latest annual report filed Mar 27, 2026.

Key statistics

Fiscal 2025 from SEC filings. Methodology
Revenue (FY25)$72,102
Revenue growth+0.0%
Revenue, 5-yr CAGR+12.0%
Gross margin38.6%
Operating margin−5937.0%
Net margin−5863.5%
ROICn/a
Return on equity−74.6%
Debt / equityn/a
Free cash flown/a
FCF marginn/a
Share count change+127.8%

Financials

Fiscal years, $M
Item20212022202320242025
Revenuen/a0000
Operating income−3−4−4−5−4
Net income4−4−4−4−4
Free cash flown/an/an/an/an/a

Recent filings

From SEC EDGAR

Peers

Pharmaceutical preparations